Compugen Announces $15 Million Funding Agreement for its Keddem Subsidiary

News   Mar 21, 2013

 
Compugen Announces $15 Million Funding Agreement for its Keddem Subsidiary
 
 
 

RELATED ARTICLES

Safety and Efficacy of MERS Treatment Confirmed in Phase I Trial

News

An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.

READ MORE

Scientists Cloak Anti-Cancer Drugs in Particles to Target and Destroy Tumor Cells

News

Scientists now report results showing that, by cloaking anti-cancer drugs in a specially designed particle, they could target and destroy tumor cells deep inside a malignant mass in vitro.

READ MORE

Marburg Virus: Workings of the First Promising Treatment Revealed

News

Scientists have discovered the workings of the first promising treatment for Marburg virus, a pathogen with the same pandemic potential as Ebola virus. The research builds on previous studies showing that an antibody called MR191 can neutralize Marburg—though no one knew exactly how it targeted the virus.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE